Reporting of postmarket outcomes for the Sapien 3 and Mitraclip devices frequently misclassified patient deaths as device malfunction or other outcomes. Misclassification for Sapien 3 involved 17.5% of patients deaths, and involved 24.7% of patient deaths for Mitraclip. These outcomes are important for the public and physicians to understand when d
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
October 10, 2019
Minimizing Permanent Pacemaker Following Repositionable Self-Expanding Transcatheter Aortic Valve Replacement
August 29, 2019
Using an approach that minimizes valve depth relative to the membranous septum, the authors reduced the need for permanent pacemaker placement to a reliable and predictable 3% compared to the accepted standard of 10%.
August 16, 2019
The FDA-approved use of TAVR has now expanded to low-risk patients with severe aortic stenosis. This includes both Edwards Lifesciences' Sapien 3 and Sapien 3 Ultra as well as Medtronic's Evolut R and Evolut PRO.
Early Migration of a Self-Expanding Transcatheter Aortic Valve Prosthesis Causing Coronary Occlusion: A Practical Technique for Surgical Explantation
July 24, 2019
The authors report a case of early migration of a self-expanding transcatheter aortic valve prosthesis causing coronary obstruction and myocardial infarction.
Transcatheter Valve-in-Valve Versus Surgical Replacement of Failing Stented Aortic Biological Valves
July 20, 2019
This retrospective study by Sedeek et al aimed to compare the outcomes of patients undergoing transcatheter aortic valve replacement (TAVR) valve-in-valve (n=90) versus surgical replacement (SAVR) (n=260) of failing stented aortic biological valves in a cohort of 350 patients .
July 19, 2019
Patient Care and General Interest
Feasibility of Repeat TAVR After SAPIEN 3 TAVR: A Novel Classification Scheme and Pilot Angiographic Study
July 9, 2019
Transcatheter aortic valve replacement (TAVR) is expanding to younger patients, but the feasibility of TAVR in failing transcatheter aortic valves (TAV) remains unknown.
July 6, 2019
The Washington University group compared operator radiation exposure during transcatheter valve implantation when performed via a transfemoral versus an alternative access approach, when performed in a catheterization lab versus a hybrid operating room (OR), and investigated the potential benefit of disposable shielding.
In Global News: Updated US TAVR Coverage Decision, 3D Modeling for Chest Wall Reconstruction, and Disparity in Eligibility for Lung Cancer Screening
June 28, 2019
Patient Care and General Interest San Francisco, California, passed an ordinance to ban the sale of e-cigarettes in the city, the first such ordinance in the USA.
June 18, 2019
This large review of over 100,000 patients undergoing transcatheter aortic valve replacement demonstrated a stroke rate of 2.3% within 30 days of the procedure, and no decrease in the rate between 2011 and 2015.